HER2-positive breast cancer enters the era of right-sized treatment
HER2-positive breast cancer has moved far beyond its original reputation as an especially aggressive subtype. In the early-stage setting, cure is now a realistic goal for many patients, while a substantial proportion of those with metastatic disease are living beyond 5 years. That shift did not happen by accident. It reflects the layered arrival of HER2-targeted antibodies, tyrosine-kinase inhibitors and antibody–drug conjugates, each one pushing the disease a little further back from its historical behavior.
The next problem is no longer whether HER2 should be targeted. It is how much treatment is enough, for whom, and at what point in the disease course intensification stops helping and starts adding avoidable toxicity.
Trastuzumab deruxtecan is moving earlier, faster than the field’s old assumptions
The most consequential development in the current treatment sequence is the rapid movement of trastuzumab deruxtecan into earlier lines of therapy. The drug is no longer confined to late metastatic rescue. Emerging roles now include the first-line metastatic setting, adjuvant treatment for high-risk residual disease, and neoadjuvant therapy. In practical terms, a drug built for resistant disease is being pulled upstream into curative-intent management and frontline metastatic care at the same time.
That expansion creates real therapeutic leverage. It also creates a sequencing problem that current evidence has not fully solved. If a potent antibody–drug conjugate is used early, which agents should follow, how long should it continue, and what happens when patients relapse after exposure to the same class? The review treats those questions as central rather than peripheral, because the clinical impact depends not just on the activity of a drug, but on where it sits inside an increasingly crowded treatment pathway.
The biologic rationale is easy to understand. A therapy that couples HER2 targeting with intracellular cytotoxic delivery can attack tumors that still depend on HER2 signaling while also reaching cells that have become harder to control with conventional antibodies alone. That design explains why the field has been willing to move it earlier, even as the evidence base is still catching up.
Early-stage disease now demands both restraint and escalation
In early-stage disease, the major theme is selective adaptation rather than blanket intensification. Patients with low-risk tumors may benefit from de-intensification, while those with stage II–III disease need well-constructed neoadjuvant backbones and those with residual disease after surgery may require post-neoadjuvant escalation. The goal is not to give everyone less or everyone more. The goal is to match the intensity of therapy to recurrence risk, biologic behavior and treatment response.
Residual disease remains a particularly important inflection point. A tumor that persists after neoadjuvant therapy has already signaled relative resistance, and that resistance changes the therapeutic calculus. Escalation in that setting is not about punishing biology; it is about using the postoperative window to eliminate microscopic disease before it declares itself clinically. The review places trastuzumab deruxtecan in that context as part of the evolving curative setting, while also emphasizing that the field still lacks full clarity on duration, sequencing and optimal patient selection.
A single sentence captures the shift in philosophy: the same subtype now requires both de-escalation and escalation, sometimes within the same disease stage.
Maintenance therapy is becoming a second decision point in metastatic disease
Advanced HER2-positive breast cancer is no longer managed with a simple induction-then-maintenance template. After induction therapy, maintenance choices are becoming more complex, particularly around trastuzumab–pertuzumab-based approaches. The review points to maintenance strategies that may incorporate palbociclib or tucatinib, reflecting a broader effort to keep disease suppressed after the initial response phase without defaulting to continuous cytotoxic therapy.
This matters because metastatic control depends on cumulative exposure, tolerability and patient preference as much as on response depth. A maintenance regimen that is biologically active but poorly tolerated may not translate into durable benefit in the real world. Conversely, a regimen that is easier to sustain may preserve quality of life while extending disease control. The field is now trying to define that balance with more precision.
The newest complication is the arrival of first-line trastuzumab deruxtecan plus pertuzumab. That combination broadens the frontline menu, but it also raises a direct question about what should happen after it stops. The optimal treatment duration and the best subsequent sequence remain uncertain, and those uncertainties will shape routine practice as much as the initial response data do.
Biomarkers are starting to replace guesswork with structure
The review places substantial emphasis on biomarkers that may refine treatment selection across the disease continuum. Quantitative HER2 expression, intrinsic subtype, imaging response and circulating tumor DNA are all positioned as tools that could help identify which patients need intensification and which can safely avoid it. These are not abstract research toys. They are the types of measurements that could eventually prevent overtreatment in one patient while identifying resistance early in another.
Tissue biomarkers can clarify how strongly a tumor still depends on HER2 signaling. Plasma assays can track molecular persistence after therapy begins. Dynamic imaging can show whether a lesion is shrinking in a way that predicts durable control or only temporary suppression. Each modality answers a different part of the same clinical question: is the current treatment doing enough, and if not, how quickly should the plan change?
The appeal of biomarker-guided care is straightforward. HER2-positive breast cancer is no longer a single therapeutic lane. It is a disease spectrum in which the same label can describe tumors with different levels of expression, different sensitivity to HER2 blockade and different resistance patterns after exposure to modern regimens.
The central challenge is not access to drugs, but calibration
This review is ultimately about calibration. The field has already achieved something remarkable by converting a once-feared subtype into a disease with high curability in early-stage cases and meaningful long-term survival in metastatic cases. The problem now is not a shortage of active agents. It is deciding how to sequence them, how long to continue them and which patients should receive the most aggressive combinations.
Two pressures run in opposite directions. One is the temptation to intensify therapy because the arsenal keeps expanding. The other is the recognition that every added layer brings toxicity, cost and the possibility of diminishing returns. Right-sizing therapy means resisting both reflexive escalation and premature de-escalation.
The review leaves several practical questions open. Duration of first-line trastuzumab deruxtecan–based therapy, retreatment after prior exposure, and the best way to integrate maintenance options remain unresolved. Biomarkers may help narrow those gaps, but they are not yet a complete answer. For now, HER2-positive breast cancer is being treated with more precision than ever before, yet the most important decisions are still being refined in real time.
Evidence is expanding faster than the rules that govern it
Recent and forthcoming studies are feeding the pace of change, including trials of trastuzumab deruxtecan in residual early breast cancer, neoadjuvant regimens for high-risk disease and maintenance strategies built around tucatinib. The momentum is clear. What is not yet settled is how these new data should be layered into a single durable algorithm that preserves cure rates, extends survival in metastatic disease and avoids unnecessary exposure when a lighter touch would do.
That is the practical frontier now: not whether HER2-positive breast cancer is treatable, but how to make treatment as precise as the biology it is meant to control.